Home > Oncology > ASCO 2022 > PALOMA-2: shaky OS results of palbociclib in ER-positive/HER2-negative breast cancer

PALOMA-2: shaky OS results of palbociclib in ER-positive/HER2-negative breast cancer

Presented By
Prof. Richard Finn, UCLA David Geffen School of Medicine, CA, USA
Conference
ASCO 2022
Trial
Phase 3, PALOMA-2
The overall survival (OS) was not significantly longer in patients with ER-positive/HER2-negative advanced breast cancer who received letrozole plus palbociclib than in those who received letrozole plus placebo. However, post-hoc subgroup analysis revealed that patients with a disease-free interval (DFI)>12 months may live longer if they take additional palbociclib. The randomised, double-blind, phase 3 PALOMA-2 trial (NCT01740427) was designed to assess the benefits of adding the CDK4/6 inhibitor palbociclib to endocrine therapy. The primary analysis demonstrated that the median progression-free survival (PFS) of patients on palbociclib plus letrozole (n=444) was significantly longer than that of patients who received letrozole and placebo (n=222; 24.8 months vs 14.5 months; HR 0.58; P<0.001) [1]. Prof. Richard Finn (UCLA David Geffen School of Medicine, CA, USA) presented the final OS an...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on